STLN
Starling Oncology, Inc.
Company Overview
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
SectorHealthcare
IndustryMedical - Care Facilities
Market Cap$670.9M
Last DividendNone
Employees641
CEODaniel Virnich
Valuation
Current Price$6.71
Fair Value?$000.00
Valuation?No valuation
Current PE ?N/Aⓘ
Hist. PE ?N/Aⓘ
EPS (TTM) ?-0.35
Forward EPS Growth ?—
Historical Growth ?5.17%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro
Price?
EPS?
Revenue?
Equity?
ProAvailable on the Pro plan
Free Cash Flow?
ProAvailable on the Pro plan
Long Term Debt?
ProAvailable on the Pro plan
Net Profit?
ProAvailable on the Pro plan
Shares Outstanding?
ProAvailable on the Pro plan
Last updated: 10/23/2026, 10:20:49 PM